Abstract
Background ITGA3 is a member of the integrin family, a cell surface adhesion molecule that can interact with extracellular matrix (ECM) proteins. The purpose of this study was to explore the significance of ITGA3 expression in the prognosis and clinical diagnosis of breast cancer patients.MethodsOncomine, the Human Protein Atlas (HPA) and UALCAN were used to analyze the expression of ITGA3 in various cancers. PrognoScan, GEPIA, Kaplan–Meier plotter and Easysurv were utilized to analyze the prognosis of ITGA3 in certain cancers. Based on TCGA data, a receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance of ITGA3 expression. cBio-Portal and MethSurv were used to evaluate the genomic mechanism. LinkedOmics, NetworkAnalyst and Metascape were used to build the signaling network. TIMER is a web server for comprehensive analysis of tumor infiltrating immune cells and tumor infiltrating lymphocytes (TILs).ResultsThe expression of ITGA3 in normal breast tissues was greater than that in breast cancer tissues at both the mRNA and protein levels. High expression of ITGA3 was associated with better prognosis of breast cancer patients. ROC analysis indicated that ITGA3 had significant diagnostic value. Genomic analysis revealed that promoter methylation of ITGA3 leads to transcriptional silencing, which may be one of the mechanisms underlying ITGA3 downregulation in BRCA. Immune infiltration analysis showed that ITGA3 may be involved in the recruitment of immune cells.ConclusionsThis study identified ITGA3 as a novel biomarker to estimate the diagnosis and prognosis of breast cancer. In addition, ITGA3 is involved in ECM regulation and immune cell infiltration.
Highlights
Breast cancer is the primary killer of women
We found that the mRNA expression of ITGA3 in bladder cancer, brain and CNS cancer, cervical cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, leukemia, lymphoma, melanoma, myeloma, ovarian cancer, pancreatic cancer and other cancers was higher than that in adjacent normal tissues, while in breast cancer, colorectal cancer, lung cancer, prostate cancer and sarcoma, the expression was lower than that in normal controls (Figure 1A)
The results showed that ITGA3 was markedly overexpressed in 13 types of cancer (BLCA, ESCA, CHOL, HNSC, KIRC, KIRP, LIHC, STAD, THCA) compared with the corresponding normal controls
Summary
Breast cancer is the primary killer of women. Breast cancer remains the leading cancerrelated cause of disease for women [1, 2]. Metastasis is considered to be the main cause of the high mortality of breast cancer [3]. Breast cancer is highly heterogeneous [4], mainly in terms of treatment with surgery and chemotherapy. The combination of targeted therapy and immunotherapy has achieved certain results, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/PD-L1) antagonists in small numbers of patients with metastatic breast cancer [5]. The purpose of this study was to explore the significance of ITGA3 expression in the prognosis and clinical diagnosis of breast cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
